High cyclic citrullinated peptide antibodies need to first determine whether the patient can be diagnosed with rheumatoid arthritis, if the patient is rheumatoid arthritis, the cyclic citrullinated peptide antibody level can be lowered through the use of improving the condition of the anti-rheumatic drugs, biologics and other drugs.
Cyclic citrullinated peptide antibodies are specific autoantibodies for rheumatoid arthritis and are used clinically as a diagnostic criterion for rheumatoid arthritis. A high level of cyclic citrullinated peptide antibody is very likely to cause rheumatoid arthritis.
To determine whether a patient has a diagnosis of rheumatoid arthritis with high cyclic citrullinated peptide antibodies, it is necessary to first determine whether the patient has a diagnosis of rheumatoid arthritis. If the patient has rheumatoid arthritis, the level of cyclic citrullinated peptide antibodies can be lowered through the use of medications such as condition-improving antirheumatic drugs and biological agents.
1. Commonly used anti-rheumatic drugs to improve the condition, such as methotrexate, leflunomide, etc. During the use of these drugs, the patient’s liver and kidney function, blood routine and other indicators should be closely monitored.
2. Biological agents, such as adalimumab and tofacitib, can be used to treat rheumatoid arthritis. After the condition of rheumatoid arthritis is stabilized, the level of cyclic citrullinated peptide antibody may decrease to a certain extent.
However, since the level of cyclic citrullinated peptide antibody is not synchronized with the patient’s condition and cannot fully reflect the changes in the patient’s condition, cyclic citrullinated peptide antibody cannot be completely converted to negative after treatment. It is recommended that patients go to the rheumatology and immunology departments of regular hospitals for detailed consultation and follow the doctor’s instructions for standardized treatment, and do not use medication on their own.